| Drug Name: | LAQ824 (404951-53-7) |
|---|---|
| PubChem ID: | 6445533 |
| SMILES: | C1=CC=C2C(=C1)C(=CN2)CCN(CCO)CC3=CC=C(C=C3)/C=C/C(=O)NO |
| InchiKey: | BWDQBBCUWLSASG-MDZDMXLPSA-N |
| Therapeutic Category: |
| Molecular Weight (dalton) | : | 379.46 |
| LogP | : | 2.7235 |
| Ring Count | : | 3 |
| Hydrogen Bond Acceptor Count | : | 4 |
| Hydrogen Bond Donor Count | : | 4 |
| Total Polar Surface Area | : | 88.59 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Apoptosis | Heat shock protein HSP 90 (P07900) | Depleted the mRNA and protein expression of BCR-ABL in human chronic myeloid leukemia blast crisis (CML-BC) cells;induced the expression of the cell cycle-dependent kinase inhibitors p21 and p27 and caused cell cycle G(1)-phase accumulation and apoptosis of CML-BC cells. [ ADR Type 2 ] | Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category
| Toxicity | Source |
|---|